Uveitis treatment Market By Disease Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Uveitis treatment Market
Uveitis treatment Market: By Disease Type(Anterior (Acute), Posterior, Intermediate & Pan uveitis), By Treatment (Anti-inflammatory Medicines, Antibiotic or antiviral medicines & Immunosuppressive medicines) & By Geography-Forecast (2016-2021)
Report Code : HCR 0156
Updated Date: 25 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Uveitis treatment – Market Overview
2. Executive Summary
3. Uveitis treatment Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Uveitis treatment – Market Forces
   4.1. Drivers
      4.1.1. Growing aging population and increasing eye disorders
      4.1.2. Strong R&D and Pipe line for uveitis treatment drugs
   4.2. Restraints
      4.2.1. Low awareness about uveitis and eye disorders
   4.3. Opportunities
      4.3.1.  Increasing medical infrastructure in developing economies
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Uveitis treatment Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Global Uveitis treatment Market By Disease Type
   6.1. Anterior uveitis
      6.1.1. Acute Anterior uveitis
   6.2. Posterior uveitis
   6.3. Intermediate uveitis
   6.4. Panuveitis
7. Global Uveitis treatment Market By Treatment
   7.1. Anti-inflammatory Medicines
   7.2. Antibiotic or antiviral medicines
   7.3. Immunosuppressive medicines
8. Global Uveitis treatment Market By Geography
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Uveitis treatment – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles
   10.1. Amdipharm Mercury Company Limited 
      10.1.1.  Introduction
      10.1.2. Financials
      10.1.3. Key Insights
      10.1.4. Key Strategy
      10.1.5. Product Portfolio
      10.1.6. SWOT Analysis
   10.2. Novartis Pharmaceuticals AG 
      10.2.1. Introduction
      10.2.2. Financials
      10.2.3. Key Insights
      10.2.4. Key Strategy
      10.2.5. Product Portfolio
      10.2.6. SWOT Analysis
   10.3. Santen pharmaceuticals    
      10.3.1.  Introduction
      10.3.2. Financials
      10.3.3. Key Insights
      10.3.4. Key Strategy
      10.3.5. Product Portfolio
      10.3.6. SWOT Analysis
   10.4. Allergan, Inc.   
      10.4.1. Introduction
      10.4.2. Financials
      10.4.3. Key Insights
      10.4.4. Key Strategy
      10.4.5. Product Portfolio
      10.4.6. SWOT Analysis
   10.5. Bausch & Lomb Incorporated
      10.5.1. Introduction
      10.5.2. Financials
      10.5.3. Key Insights
      10.5.4. Key Strategy
      10.5.5. Product Portfolio
      10.5.6. SWOT Analysis
   10.6. Regeneron Pharmaceuticals Inc.
      10.6.1. Introduction
      10.6.2. Financials
      10.6.3. Key Insights
      10.6.4. Key Strategy
      10.6.5. Product Portfolio
      10.6.6. SWOT Analysis
   10.7. AbbVie Inc.
      10.7.1. Introduction
      10.7.2. Financials
      10.7.3. Key Insights
      10.7.4. Key Strategy
      10.7.5. Product Portfolio
      10.7.6. SWOT Analysis
   10.8. Enzo Biochem Inc.
      10.8.1. Introduction
      10.8.2. Financials
      10.8.3. Key Insights
      10.8.4. Key Strategy
      10.8.5. Product Portfolio
      10.8.6. SWOT Analysis
   10.9. Alcon, Inc.
      10.9.1. Introduction
      10.9.2. Financials
      10.9.3. Key Insights
      10.9.4. Key Strategy
      10.9.5. Product Portfolio
      10.9.6. SWOT Analysis
   10.10. OphthaliX Inc.
      10.10.1. Introduction
      10.10.2. Financials
      10.10.3. Key Insights
      10.10.4. Key Strategy
      10.10.5. Product Portfolio
      10.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Expert Insights
Uveitis can be defined as an internal inflammation of the eye. The condition involves the middle layers of the eye, also called the uveal tract or uvea. The uvea includes the iris (colored part of the eye), choroid (a thin membrane containing many blood vessels), and the ciliary body (the part of the eye that joins these together). Uveitis is caused due to infection with a virus, fungus, bacteria, parasite, inflammatory disease affecting other parts of the body, or injury to the eye. Globally increasing aging population coupled with increasing the registered instances of eye disorders are expected to be the key growth drivers for uveitis treatment.

This report identifies the uveitis treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to uveitis treatment market.

Uveitis treatment Market

Globally North America dominated the market for uveitis treatment in 2015 due to high patient awareness levels about eye disorders and advanced healthcare infrastructure in the region. North America was followed by Europe and Asia-Pacific as the second and third largest markets respectively for Uveitis treatment in 2015. Demand for Uveitis treatment in Asia-Pacific is expected to witness fastest growth in the near future due to increasing aging population, government initiatives to curb eye disorders in the region coupled with increasing awareness and developing medical infrastructure in the region.

This report on global uveitis treatment is segmented on the basis of various types of uveitis disease, treatment type and market size in various geographical regions.
  • On the basis of types of uveitis disease this report classified as follows covering all major types of uveitis as follows: Anterior uveitis (Acute Anterior uveitis), Posterior uveitis, Intermediate uveitis and Panuveitis
  • On the basis of available treatment for uveitis, this report is segmented as follows covering all the major type of available treatment:  Anti-inflammatory Medicines, Antibiotic or antiviral medicines and Immunosuppressive medicines
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for uveitis treatment in each of the region.

This report identifies all the major companies operating in the global uveitis treatment market. Some of the major companies’ profiles in detail are as follows:
  • Amdipharm Mercury Company Limited 
  • Novartis Pharmaceuticals AG 
  • Santen pharmaceuticals    
  • Allergan, Inc.   
  • Bausch & Lomb Incorporated
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll